Cue Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cue Biopharma, Inc. (CUE) on April 19, 2023. The report discloses a corporate governance event: the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
On April 19, 2023, Pamela Garzone was appointed to the Board of Directors following a recommendation by the Corporate Governance and Nominating Committee. No other material changes to the company's operations or financial status are reported in this document.
Guidance, Outlook, and Compensation Details
- Compensation: Dr. Garzone will be compensated in accordance with the Company's Director Compensation Policy.
- Equity Grant: Upon appointment, Dr. Garzone was granted an option to purchase 40,000 shares of common stock.
- Vesting Schedule: The option vests over three years, with one-third vesting on the one-year anniversary of the grant date and the remainder vesting in eight equal quarterly installments.
- Indemnification: Dr. Garzone entered into a standard indemnification agreement, under which the Company may be required to cover certain expenses, including legal fees and judgments, arising from her service as a director.
Investor Verification Checklist
- Verify the full text of the Director Compensation Policy referenced in the April 12, 2023 Form 8-K (Exhibit 10.1).
- Confirm the specific exercise price of the 40,000 share option granted to Dr. Garzone, as it is not explicitly stated in this summary text.
- Review the standard indemnification agreement filed as Exhibit 10.11 to the 2022 Form 10-K for specific liability caps or exclusions.
- Check subsequent filings for any changes to the Board composition or Dr. Garzone's committee assignments.